DRUG
Cagrilintide D
Cagrilintide D will be administered subcutaneously.
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
Status
Recruiting
Phase
Phase 1
Enrollment
234
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintide version B, and which treatment participants receive is decided by chance. Participants will be in this clinical study for about 6 months.
Interventions
Treatment arms and agents.
DRUG
Cagrilintide B and placebo semaglutide I
Cagrilintide B and placebo semaglutide I will be administered subcutaneously
Timeline
From registration to results.
First posted
May 19, 2026
Study start
May 18, 2026
Primary completion
May 28, 2027
Study completion
Jun 1, 2027
Results posted
Not reported
Registry updated
Jun 26, 2026
Outcomes
What the study measures.
Primary outcomes
AUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in hour nanomoles per litre (h\*nmol/L)
Cmax,ss: maximum concentration of total cagrilintide at steady state after 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in nanomoles per litre (nmol/L).
Secondary outcomes
tmax,ss: time since last dosing to maximum concentration of totala cagrilintide at steady state after 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in hours.
t½,ss: terminal half-life of total cagrilintide at steady state after 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 162 (post-dose)
Measured in hours.
Vz/F: the apparent volume of distribution of total cagrilintide during elimination after the 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in litre.
CL/F: total apparent clearance of total cagrilintide after the 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in litre per hours.
AUC,ss: area under the cagrilintide and metabolites concentration-time curve at steady state after the 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in hours\*nmol/L.
Cmax,ss: maximum concentration of cagrilintide and metabolites at steady state after the 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in nmol/L.
tmax,ss: time since the last dosing to maximum concentration of cagrilintide and metabolites at steady state after the 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in hours.
t½,ss: terminal half-life of cagrilintide parent at steady state after the 5th dosing of cagrilintide s.c.
Time frame · Day 113 (pre-dose) to Day 120 (post-dose)
Measured in hours.
AUC,ss: area under the total cagrilintide concentration-time curve at steady state after the 4th dosing of cagrilintide s.c
Time frame · Day 22 (pre-dose) to Day 29 (post-dose)
Measured in hours\*nmol/L.
Cmax,ss: maximum concentration of total cagrilintide at steady state after the 4th dosing of cagrilintide s.c.
Time frame · Day 22 (pre-dose) to Day 29 (post-dose)
Measured in nmol/L.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 64 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Aged 18-64 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 27.0 and 34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Previous participation in study(s) with an amylin analogue. Participation is defined as randomisation. * Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Study locations
1 registered sites.
Germany. Showing up to 24 locations stored in the fast local snapshot.
Parexel International GmbH
Berlin, Germany
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Cagrilintide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
609
2026-07
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
3,400
2026-07
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Novo Nordisk · Cardiovascular Disease
Phase 3
Active, not recruiting
7,101
2026-07
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk · Diabetes Mellitus, Type 2
Phase 3
Completed
1,023
2026-07
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk · Overweight · Obesity
Phase 3
Recruiting
460
2026-07
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Novo Nordisk · Diabetes Mellitus, Type 2
Phase 2
Withdrawn
0
2026-07
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Novo Nordisk · Overweight · Obesity
Phase 3
Withdrawn
0
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.